|
Article Excerpt
The Eleventh Circuit, in Schering-Plough Corporation v. FTC, No. 04-10688 (11th Cir. March 8, 2005), recently vacated a Federal Trade Commission (FTC) order requiring pharmaceutical companies to cease enforcement of certain patent litigation settlement agreements involving generic versions of patented drugs.
One of the underlying patent disputes at issue in Schering-Plough, by way of illustration, involved Schering's branded extended release potassium chloride product, K-Dur 20. Schering owns a formulation patent on K-Dur 20's extended release coating (the '743 patent) that expires in September 2006.
Upsher-Smith Laboratories (Upsher), one of Schering's competitors, sought approval from the U.S. Food and...
|
|
More articles from Mondaq Business Briefing
The Federal Circuit Expands the Extraterritorial Reach of the U.S. Pat..., May 13, 2005
The Interplay Between Patents and Trade Secrets in Litigation., May 13, 2005
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
|
